RESUMEN
BACKGROUND: Sarcopenia was reported to be associated with poor clinical outcome, higher incidence of community-acquired pneumonia, increased risk of infections and reduced survival in different clinical settings. The aim of our work is to evaluate the prognostic role of sarcopenia in patients with the 2019 novel coronavirus disease (COVID-19). MATERIALS AND METHODS: 272 COVID-19 patients admitted to the University Hospital of Modena (Italy) from February 2020 to January 2021 were retrospectively studied. All included patients underwent a chest computed tomography (CT) scan to assess pneumonia during their hospitalization and showed a positive SARS-CoV-2 molecular test. Sarcopenia was defined by skeletal muscle area (SMA) evaluation at the 12th thoracic vertebra (T12). Clinical, laboratory data and adverse clinical outcome (admission to Intensive Care Unit and death) were collected for all patients. RESULTS: Prevalence of sarcopenia was high (41.5%) but significantly different in each pandemic wave (57.9% vs 21.6% p < 0.0000). At the multivariate analysis, sarcopenia during the first wave (Hazard Ratio 2.29, 95% confidence intervals 1.17 to 4.49 p = 0.0162) was the only independent prognostic factor for adverse clinical outcome. There were no significant differences in comorbidities and COVID19 severity in terms of pulmonary involvement at lung CT comparing during the first and second wave. Mixed pattern with peripheral and central involvement was found to be dominant in both groups. CONCLUSION: We highlight the prognostic impact of sarcopenia in COVID-19 patients hospitalized during the first wave. T12 SMA could represent a potential tool to identify sarcopenic patients in particular settings. Further studies are needed to better understand the association between sarcopenia and COVID-19.
Asunto(s)
COVID-19 , Sarcopenia , Humanos , Pandemias , Estudios Retrospectivos , SARS-CoV-2 , Sarcopenia/diagnóstico , Sarcopenia/epidemiologíaRESUMEN
The aim of this study was to understand and measure the lower limbs muscular activation patterns both in healthy and spinal cord injured (SCI) subjects during robot-assisted locomotor exercise. Electromyographic (EMG) activity of four leg's muscles (rectus and biceps femoris, tibialis anterioris and gastrocnemius) was recorded and analyzed at two different percentages of body weight support, three stepping velocities and three different modalities. SCI subjects were recorded also after four weeks training to evaluate the effectiveness of lower limb robot-assisted rehabilitative treatment. A multi-factor ANOVA on the integrated muscle activity (IEMG) parameters both in healthy and SCI subjects was performed. Higher muscular activities both in healthy subjects and SCI patients were found during the exercises using the "DGO active" modality and higher stepping velocities. A significant increased bilateral muscular activity was observed in each SCI subject after the rehabilitation treatment. The method proposed to analyze EMG data provides a quantitative description of the lower limb muscular recruitment and can contribute to identify the optimal rehabilitation treatment's conditions.
Asunto(s)
Electromiografía/métodos , Robótica/instrumentación , Robótica/métodos , Traumatismos de la Médula Espinal/rehabilitación , Adulto , Femenino , Humanos , Extremidad Inferior/fisiología , Masculino , Persona de Mediana Edad , Movimiento/fisiología , Músculo Esquelético/fisiologíaRESUMEN
Currently the study of infants grasping development is purely clinical, based on functional scales or on the observation of the infant while playing; no quantitative variables are measured or known for diagnosis of eventually disturbed development. The aim of this work is to show the results of a longitudinal study achieved by using a "baby gym" composed by a set of instrumented toys, as a tool to measure and stimulate grasping actions, in infants from 4 to 9 months of life. The study has been carried out with 7 healthy infants and it was observed, during infants development, an increase of precision grasp and a reduction of power grasp with age. Moreover the forces applied for performing both precision and power grasp increase with age. The proposed devices represent a valid tool for continuous and quantitative measuring infants manual function and motor development, without being distressful for the infant and consequently it could be suitable for early intervention training during the first year of life. The same system, in fact, could be used with infants at high risk for developmental motor disorder in order to evaluate any potential difference from control healthy infants.
Asunto(s)
Fuerza de la Mano/fisiología , Monitoreo Ambulatorio/instrumentación , Dinamómetro de Fuerza Muscular , Juego e Implementos de Juego , Transductores de Presión , Diseño de Equipo , Análisis de Falla de Equipo , Femenino , Humanos , Lactante , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
Sucralfate is a drug used in the treatment of gastric and duodenal ulcer; it is cytoprotective and able to increase the bioavailability of several growth factors, modulating the wound healing process. In this study we tested the possible therapeutic effect of Sucralfate in the treatment of ulcerative lesions occurring in uterine cervix; to investigate such effect we used an experimental rat model of cervicitis in which the uPAR and EGFR expression were evaluated. Cervicitis was induced in wild and ovariectomized Wistar female rats by an acetic acid-soaked tampon. The animals were divided into two main groups (4 and 7 days) and Sucralfate was administered topically until the day they were sacrificed. In order to distinguish physiological and drug-induced healing, quantitative and qualitative uPAR and EGFR expression were evaluated by using Western blot and Immunohistochemistry techniques. Western blot analysis demonstrated an increased expression of both receptors after 4 days from wounding in wild and ovariectomized animals. In particular in ovariectomized animals the expression of uPAR and EGFR increased after 4 days while it reduced following the administration of Sucralfate. In wild rats the same was observed for uPAR expression, while EGFR was different; in fact, its expression increased significantly at day 4 in the animals treated with the drug and only at day 7 in those untreated. Immunohistochemistry highlighted a noteworthy epithelial colocalization of EGFR and uPAR after 4 days in the animals treated with Sucralfate. We conclude that Sucralfate can promote the healing of ulcerative cervicitis and moreover, it reduces the normal healing time because of its modulatory property on uPAR and EGFR expression.
Asunto(s)
Antiulcerosos/uso terapéutico , Receptores ErbB/análisis , Receptores de Superficie Celular/análisis , Sucralfato/uso terapéutico , Cervicitis Uterina/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Femenino , Inmunohistoquímica , Ovariectomía , Ratas , Ratas Wistar , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Sucralfato/farmacología , Cervicitis Uterina/metabolismoRESUMEN
There is growing interest in osteoinductive agents for fracture healing especially in patients with non-union or delayed-union fractures. The aim of the present study is the assessment of the association of Vitamins D3 and K1 on proliferation and differentiation of human mesenchymal stem cells (hMSCs) derived from fracture sites in view of a possible clinical use. The synergic effect of Vitamin D3 and Vitamin K2 in preventing osteoporosis has been documented in clinical practice; however no reports investigating this association for fracture healing are present. Our data show a different outcome on cell proliferation linked to the different timing of drug administration as well as a synergic effect of the two vitamins on cell differentiation. The high level of osteocalcin and carboxylated osteocalcin detected in hMSCs treated with the association of the two vitamins in comparison with controls and with single vitamin administration underline the differentiation of these cells into osteoblastic phenotype. Our results indicate for the first time that vitamin D3 and K1 association is able to modulate in vitro the differentiation towards osteoblastic phenotype of hMSCs derived from fracture sites, thus offering clinicians a promising and low-cost strategy for reparative osteogenesis.
Asunto(s)
Diferenciación Celular/efectos de los fármacos , Fracturas Óseas/patología , Células Madre Mesenquimatosas/citología , Osteoblastos/patología , Vitamina D/farmacología , Vitamina K/farmacología , Supervivencia Celular/efectos de los fármacos , Hematoma/patología , Humanos , Células Madre Mesenquimatosas/efectos de los fármacos , Células Madre Mesenquimatosas/patología , Células Madre Mesenquimatosas/fisiología , Osteoblastos/citología , Osteoblastos/efectos de los fármacos , Osteoblastos/fisiología , Osteocalcina/efectos de los fármacos , Osteocalcina/metabolismo , Osteoporosis/prevención & control , Vitamina D/uso terapéutico , Vitamina K 1/uso terapéuticoRESUMEN
OBJECTIVE AND BACKGROUND: In the last 35 years tumour markers (TM) have gained currency in clinical practice. However, in the light of indications by international guidelines, their use is often unjustified. Our aim was to quantify the use of some of the most common TM, assessing their appropriateness and their efficacy in an Internal Medicine Unit. METHODS: In the three Internal Medicine Units of the Department of Internal Medicine of Policlinico of Modena we have carried out a retrospective analysis of the assessment of the main TM (CEA, CA19.9, CA 125, CA 15.3, NSE). The analysis was divided into two distinct phases: (I) quantitative phase, in order to assess the scale of the problem in economical terms; (II) qualitative phase, in order to assess the efficacy of the tests and the appropriateness of their use. RESULTS: (I) At last one of the considered TM was requested in 5102 out of the 8253 admitted patients (62%) (period 2001-2003). The trend was similar in all three units examined. (II) The qualitative analyses revealed: (1) the most common motivation for their use (79%) was diagnostic, mostly prior to any other test; (2) a mere 5% of the requests were appropriate according to the international literature; and (3) TM showed a low positive predictive value when used for diagnosis in an unselected population such as that of an Internal Medicine unit. CONCLUSIONS: The results of our study showed that TM determination represents an overall cost for Internal Medicine units and that there is a high inappropriateness in their use compared to what it is suggested by international guidelines. Though the TM is a low-cost test when used correctly, it seems an unnecessary expense if not adequately incorporated into the decision making process.
Asunto(s)
Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/economía , Neoplasias/sangre , Neoplasias/diagnóstico , Anciano , Anciano de 80 o más Años , Antígeno Ca-125/sangre , Antígeno CA-19-9/sangre , Antígeno Carcinoembrionario/sangre , Femenino , Adhesión a Directriz , Humanos , Masculino , Persona de Mediana Edad , Mucina-1/sangre , Guías de Práctica Clínica como Asunto , Estudios RetrospectivosRESUMEN
The aim of this work was to investigate the possible protective effect of a new viscosising agent, TS-polysaccharide, on corneal-derived cells (SIRC) exposed to ultraviolet-B rays. To verify this, SIRC cells were first exposed, in the absence or in the presence of TS-polysaccharide (1% w/v), for 9 s at the UV-B source and then post-incubated for 45 min at 37 degrees C. After this period the hydrogen peroxide (H(2)O(2)) accumulated in the medium and the concentration of 8-hydroxy-2'-deoxy-guanosine (8-OHdG) in cell DNA was measured. In addition, the amount of (3)H-methyl-thymidine incorporated in cellular DNA was evaluated after 18 h from irradiation. Our results show that cells exposed to UV-B rays accumulate H(2)O(2), and have higher levels of 8OHdG and a lower amount of (3)H-methyl-thymidine incorporated in DNA than control cells. In the presence of TS-polysaccharide, the H(2)O(2) and 8-OHdG accumulation, and the (3)H-methyl-thymidine incorporation were significantly reduced with respect to the values measured in cells exposed in the absence of the polysaccharide. We propose a protective role of the polysaccharide in reducing UV-B derived DNA damage to eye cells. This finding could be of some clinical importance when the polysaccharide is used as a delivery system for ophthalmic preparations.
Asunto(s)
Córnea/efectos de los fármacos , Córnea/efectos de la radiación , Desoxiguanosina/análogos & derivados , Polisacáridos/farmacología , Protectores contra Radiación/farmacología , Tamarindus/química , Timidina/análogos & derivados , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Células Cultivadas , Córnea/citología , Medios de Cultivo , ADN/efectos de los fármacos , ADN/efectos de la radiación , Desoxiguanosina/metabolismo , Proteínas del Ojo/metabolismo , Peróxido de Hidrógeno/metabolismo , Oxidación-Reducción , Polisacáridos/aislamiento & purificación , Conejos , Protectores contra Radiación/aislamiento & purificación , Timidina/metabolismo , Rayos UltravioletaAsunto(s)
Antihipertensivos/administración & dosificación , Composición de Medicamentos , Embalaje de Medicamentos , Glaucoma/tratamiento farmacológico , Conservadores Farmacéuticos , Timolol/administración & dosificación , Bacterias/crecimiento & desarrollo , Bacterias/aislamiento & purificación , Compuestos de Benzalconio , Contaminación de Medicamentos , Estabilidad de Medicamentos , Almacenaje de Medicamentos , Humanos , Soluciones OftálmicasRESUMEN
Purpose of the present investigation was to evaluate six terpene-containing essential oils for their capacity to promote permeation of estradiol (ES) through hairless mouse skin in vitro. Tests on cajuput, cardamom, melissa, myrtle, niaouli and orange oil, all used at the 10% w/w concentration in propylene glycol (PG), evidenced niaouli oil (NIA) as the best permeation promoter for ES. Tests on the main terpene components of NIA (1,8 cineole, alpha-pinene, alpha-terpineol and D-limonene), evaluated neat (10% w/w in PG) or in admixture, confirmed the better promoting activity of whole NIA. The present data point to the validity of complex terpene mixtures, such as that composing NIA, as transdermal penetration enhancers for moderately lipophilic drugs like ES.
Asunto(s)
Estradiol/farmacocinética , Aceites Volátiles/farmacocinética , Absorción Cutánea/fisiología , Terpenos/farmacocinética , Administración Cutánea , Animales , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/estadística & datos numéricos , Ratones , Ratones Pelados , Absorción Cutánea/efectos de los fármacos , Terpenos/farmacologíaRESUMEN
Acetic acid derivatives of [1,2,4]triazino[4,3-a]benzimidazole (TBI) were synthesized and tested in vitro and in vivo as a novel class of aldose reductase (ALR2) inhibitors. Compound 3, (10-benzyl[1,2,4]triazino[4,3-a]benzimidazol-3,4(10H)-dion-2-yl)acetic acid, displayed the highest inhibitory activity (IC(50) = 0.36 microM) and was found to be effective in preventing cataract development in severely galactosemic rats when administered as an eyedrop solution. All the compounds investigated were selective for ALR2, since none of them inhibited appreciably aldehyde reductase, sorbitol dehydrogenase, or glutathione reductase. The activity of 3 was lowered by inserting various substituents on the pendant phenyl ring, by shifting the acetic acid moiety from the 2 to the 3 position of the TBI nucleus, or by cleaving the TBI system to yield benzimidazolylidenehydrazines as open-chain analogues. A three-dimensional model of human ALR2 was built, taking into account the conformational changes induced by the binding of inhibitors such as zopolrestat, to simulate the docking of 3 into the enzyme active site. The theoretical binding mode of 3 was fully consistent with the structure-activity relationships in the TBI series and will guide the design of novel ALR2 inhibitors.
Asunto(s)
Acetatos/síntesis química , Aldehído Reductasa/antagonistas & inhibidores , Bencimidazoles/síntesis química , Inhibidores Enzimáticos/síntesis química , Triazinas/síntesis química , Acetatos/química , Acetatos/farmacología , Animales , Bencimidazoles/química , Bencimidazoles/farmacología , Sitios de Unión , Catarata/etiología , Catarata/prevención & control , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Galactosemias/complicaciones , Humanos , Modelos Moleculares , Soluciones Oftálmicas , Unión Proteica , Ratas , Estereoisomerismo , Relación Estructura-Actividad , Triazinas/química , Triazinas/farmacologíaRESUMEN
This report describes the efficacy of a novel mucoadhesive polymer, the tamarind seed polysaccharide, as a delivery system for the ocular administration of hydrophilic and hydrophobic antibiotics. Healthy rabbits were subjected to repeated ocular instillations with either conventional gentamicin or ofloxacin or these agents viscosified with the tamarind seed polysaccharide. Administration of viscosified preparations produced antibiotic concentrations both in the aqueous humour and cornea that were significantly higher than those achieved with the drugs alone. The increased drug absorption and the prolonged drug elimination phase obtained with the viscosified formulations indicate the usefulness of the tamarind seed polysaccharide as an ophthalmic delivery system for topical administration of antibiotics.
Asunto(s)
Antibacterianos/farmacocinética , Antiinfecciosos/farmacocinética , Humor Acuoso/metabolismo , Gentamicinas/farmacocinética , Glicosaminoglicanos/farmacocinética , Ofloxacino/farmacocinética , Administración Tópica , Animales , Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Interacciones Farmacológicas , Infecciones del Ojo/tratamiento farmacológico , Gentamicinas/uso terapéutico , Glicosaminoglicanos/uso terapéutico , Masculino , Ofloxacino/uso terapéutico , Fitoterapia , Conejos , Semillas/uso terapéuticoRESUMEN
PURPOSE: To explore the role of a natural polysaccharide extracted from tamarind seed (xyloglucan, or tamarind seed polysaccharide, TSP) on the integrin-substrate recognition system and on repair of corneal wounds. METHODS: a) Cultured human conjunctival cells were labeled by addition of a tritiated amino acid mixture. Their adhesion to laminin-coated culture wells in the absence or presence of TSP was checked by radioactivity count. b) The corneal epithelium of albino rabbits was damaged by applying a paper disc soaked with n-heptanol. The eyes were then treated with TSP, with a hyaluronate reference formulation and with normal saline solution (controls). The diameter of corneal wounds was measured daily, after fluorescein staining. RESULTS: Compared to hyaluronate, TSP slightly but significantly increased the wound healing rate. TSP 1.0% exerted a positive influence on cell adhesion to laminin, up to a certain laminin concentration. CONCLUSIONS: The ability of the polysaccharide to promote corneal wound healing might depend on its influence on the integrin recognition system.
Asunto(s)
Conjuntiva/metabolismo , Epitelio Corneal/efectos de los fármacos , Glucanos , Laminina/metabolismo , Polisacáridos/farmacología , Cicatrización de Heridas/efectos de los fármacos , Xilanos , Animales , Quemaduras Químicas/tratamiento farmacológico , Adhesión Celular/efectos de los fármacos , Células Cultivadas , Conjuntiva/citología , Epitelio Corneal/lesiones , Quemaduras Oculares/inducido químicamente , Heptanol , Humanos , Masculino , Soluciones Oftálmicas/farmacología , Plantas Medicinales , Conejos , SemillasRESUMEN
This study was aimed at verifying the performances of a mucoadhesive polysaccharide from tamarind seed (xyloglucan or TSP, tamarind seed polysaccharide) as an adjuvant for ophthalmic vehicles containing timolol. Three formulations (one experimental vehicle based on TSP and two reference commercial eye drops) containing 5 mg/ml timolol base equivalents were administered to the eyes of pigmented rabbits. Drug concentrations in tear fluid, cornea, iris-ciliary body, aqueous humor and plasma were determined, as well as intraocular pressure. The polymer under investigation, in spite of a comparatively low viscosity, produced high timolol concentrations in the ocular tissues and a low systemic absorption. The performances of the TSP vehicle were comparable to those of a reference "in situ" gelling formulation (Timoptic XE). The results point to TSP as a potentially useful adjuvant for ophthalmic delivery systems.
Asunto(s)
Antagonistas Adrenérgicos beta/farmacocinética , Segmento Anterior del Ojo/metabolismo , Sistemas de Liberación de Medicamentos , Glucanos , Presión Intraocular/efectos de los fármacos , Polisacáridos/farmacocinética , Timolol/farmacocinética , Xilanos , Antagonistas Adrenérgicos beta/farmacología , Animales , Humor Acuoso/metabolismo , Área Bajo la Curva , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Cuerpo Ciliar/metabolismo , Córnea/metabolismo , Femenino , Iris/metabolismo , Masculino , Vehículos Farmacéuticos/farmacocinética , Vehículos Farmacéuticos/farmacología , Polisacáridos/farmacología , Conejos , Lágrimas/metabolismo , Timolol/farmacología , Distribución TisularRESUMEN
Aldose reductase inhibition is one of the therapeutic strategies that has been proposed to prevent or ameliorate long term diabetic complications including retinopathy and sugar cataract. Rats were fed with a galactose rich diet and the aldose reductase inhibitor Tolrestat was topically delivered by ocular instillation. The levels of lens aldose reductase activity, galactitol and the onset of cataract were evaluated during and after treatment with the inhibitor. Topical application of 1-3% Tolrestat (10 microl) four times daily resulted, after 9 days, in a significant decrease in the enzyme activity. Well after interrupting treatment with the drug, the enzyme activity remained impaired and galactose induced cataract was prevented. Our findings may represent the basis for therapeutic plans to prevent sugar cataract by long term cyclic treatments with aldose reductase inhibitors, with reduction in drug doses and side effects.
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Catarata/prevención & control , Diabetes Mellitus Experimental/complicaciones , Inhibidores Enzimáticos/uso terapéutico , Naftalenos/uso terapéutico , Aldehído Reductasa/metabolismo , Animales , Catarata/etiología , Evaluación Preclínica de Medicamentos , Galactitol/metabolismo , Galactosa , Cristalino/enzimología , Ratas , Ratas Sprague-DawleyRESUMEN
The aim of our study was to assess whether acute variations in portal vein Doppler sonographic parameters induced by administration of a single beta-blocker agent are predictive of the long-term effects of these drugs in the prevention of a first episode of variceal bleeding. In 30 patients with liver cirrhosis at high risk for variceal bleeding, duplex Doppler sonographic parameters (maximal portal flow velocity, portal blood flow, and congestion index) were measured before and 4 h after the administration of 40 mg of propranolol. Twenty-three of these patients started chronic therapy with propanolol and were evaluated periodically (seven patients were excluded because they did not continue the therapy). The percentage of patients free from bleeding was 86.9% at the first year and 77.8% at the second year. Among a series of clinical, laboratory, and instrument-based parameters, the only one related to first bleeding, selected by the Cox regression model, was the percentage decrease in maximal portal flow velocity observed after initial administration of propranolol (P < 0.01). The best cutoff value for the percentage decrease in portal flow velocity (portal flow velocity test) was 12%. The prevalence of bleeding had been 25% (3 of 12) in patients with positive portal flow velocity test results (12% decrease or more), versus 64% (7 of 11) in patients with negative portal flow velocity test results. The actuarial probability of remaining free from bleeding (Kaplan-Meier analysis) was different in these two groups (log rank P < 0.01). The portal flow velocity test represents a safe and feasible method to predict the efficacy of beta-blockers in the prevention of a first bleeding episode in patients with cirrhosis. In patients with negative results on the portal flow velocity test, an alternative therapeutic approach should be considered.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Várices Esofágicas y Gástricas/prevención & control , Hemorragia Gastrointestinal/prevención & control , Propranolol/uso terapéutico , Ultrasonografía Doppler Dúplex , Análisis Actuarial , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Várices Esofágicas y Gástricas/diagnóstico por imagen , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Predicción , Hemorragia Gastrointestinal/diagnóstico por imagen , Humanos , Cirrosis Hepática/diagnóstico por imagen , Cirrosis Hepática/tratamiento farmacológico , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Vena Porta/diagnóstico por imagen , Vena Porta/efectos de los fármacos , Prevalencia , Pronóstico , Modelos de Riesgos Proporcionales , Curva ROC , Flujo Sanguíneo Regional/efectos de los fármacos , SeguridadRESUMEN
The present paper is concerned with the development of a simple dry eye model in the rabbit, induced by daily repeated instillations of 1.0% atropine sulphate. The evolution of the dry eye syndrome in the animals was assessed by the Schirmer I test and by examination of the cornea after fluorescein staining. The model produced rapidly some typical dry eye symptoms and could be satisfactorily used for a preliminary assessment of the protective activity of some polymeric tear substitutes. These were based on hydroxypropylmethylcellulose, sodium hyaluronate, sodium polyacrylate or tamarind gum. The latter polymer showed the best overall results. Ferning tests on the formulations were also performed: their validity as predictors of the efficacy of tear substitutes is discussed.
Asunto(s)
Síndromes de Ojo Seco/tratamiento farmacológico , Síndromes de Ojo Seco/metabolismo , Soluciones Oftálmicas/uso terapéutico , Animales , Modelos Animales de Enfermedad , Estudios de Evaluación como Asunto , Masculino , Polímeros/uso terapéutico , Conejos , Lágrimas/metabolismoRESUMEN
The prevalence of hyperinsulinemia/insulin resistance in hypertensive individuals, as well as the effects of insulin on myocytic and fibroblastic growth, are well known in both epidemiologic and animal models. To check whether there are any links between ultrasonic myocardial texture parameters and insulin level in essential hypertensives, we compared 18 essential hypertensive men (Group 1, H) with 18 age- and gender-matched healthy controls (Group 2, C) (age, 57 +/- 10 years). For all study subjects we performed ambulatory blood pressure monitoring (ABPM); conventional 2-D Doppler echocardiography for the assessment of the left ventricular mass index (LVMi) and function; quantitative analysis of digitized echocardiographic images for evaluation of cyclic variation (CVI) of mean gray level (MGL) at the septum and posterior wall levels; and 75-g 3-h oral glucose tolerance test (OGTT) for analysis of area under glycemic curve (AUGC, g/min/dL) and insulinemic curve (AUIC, mU/min/mL), as well as serum glucose and insulin peaks. Both the daily mean blood pressure (H: 109 +/- 4.6 v C: 94.6 +/- 4.6, P < .0001) and LVMi (adjusted for body surface) (H: 133 +/- 24 v C: 97 +/- 21 g/m2, P < .0001) were significantly higher in hypertensives. Values for AUIC were significantly higher in hypertensives (10.37 +/- 5.53 v 6.33 +/- 5.28), P < .032); CVI was also significantly higher in group C, for both septum (C: 40.2 +/- 16.9 v H: 15.9 +/- 18.1, P < .0001) and posterior wall (C: 44.5 +/- 19.6 v H: 20 +/- 17.5; P < .0001). There was a significant inverse correlation between AUIC and CVI for both septum (r: -0.57, P < .001) and posterior wall (r: -0.50, P < .002). The significantly higher impairment of myocardial ultrasonic texture and the higher level of the AUIC insulinemia in hypertensives, as well as the significant inverse relationship between CVI and hyperinsulinemia, are our major findings. Hyperinsulinemia/insulin resistance could cause an altered collagen/muscular ratio, which could potentially explain, at least in part, the CVI alterations detected in hypertensive patients.
Asunto(s)
Hipertensión/sangre , Insulina/sangre , Miocardio/patología , Adolescente , Adulto , Anciano , Glucemia/metabolismo , Monitoreo Ambulatorio de la Presión Arterial , Estudios de Casos y Controles , Ecocardiografía , Humanos , Hipertensión/patología , Hipertensión/fisiopatología , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Función Ventricular IzquierdaRESUMEN
Fetal growth is dependent on transplacental supply of fuels. We aimed to assess the effect of serial changes in maternal glucose tolerance and insulin secretion with advancing pregnancy on maternal-fetal outcomes. Sixty-nine healthy pregnant women were studied over the course of gestation for glucose tolerance, by oral glucose tolerance test (OGTT), and hemoglobin A(1c) (HbA(1c)), fetal intrauterine growth (by ultrasound) and pregnancy outcome. Seven women had an abnormal OGTT in the third trimester developing gestational diabetes mellitus (GDM), but none of the 12 mothers of large babies (> 3.9 kg) had GDM: the former had the highest post-load glycemic increment, despite an apparently 'normal' insulin secretory response, the latter showed the lowest post-load glucose increase in the face of the lowest insulinemic response. Neonatal body weight correlated with maternal gestational weight gain, placental weight, third trimester ratio of incremental plasma insulin and glucose integrated areas under the curve and first and second trimester HbA(1c) levels. Fetal growth indices (femur length, biparietal diameter and abdominal circumference) were correlated with both HbA(1c) and 2h OGTT. Fetal growth rate is confirmed as being associated with maternal glycemic equilibrium, but one of the main determinants of high infant birthweight seems to be an enhanced maternal insulin sensitivity, accompanied by remarkable gestational weight gain.
Asunto(s)
Desarrollo Embrionario y Fetal/fisiología , Glucosa/metabolismo , Insulina/metabolismo , Embarazo/metabolismo , Adulto , Área Bajo la Curva , Peso al Nacer , Diabetes Gestacional/metabolismo , Femenino , Prueba de Tolerancia a la Glucosa , Hemoglobina Glucada , Humanos , Recién Nacido , Masculino , Estudios Prospectivos , Aumento de PesoRESUMEN
The complexation of econazole with the mucoadhesive polycarbophil was found to significantly improve the therapeutic benefit of the drug in the topical treatment of experimental vaginal candidiasis in mice, while no difference in the antimycotic activity exerted by econazole and polycarbophil-econazole could be detected in vitro.
Asunto(s)
Resinas Acrílicas/administración & dosificación , Antifúngicos/administración & dosificación , Candidiasis Vulvovaginal/tratamiento farmacológico , Econazol/administración & dosificación , Administración Tópica , Animales , Femenino , Ratones , Ratones Endogámicos CBARESUMEN
The bioavailability of timolol and aceclidine after the ocular instillation of each drug (timolol 0.5% or aceclidine 2%) or both combined (timolol 0.5% + aceclidine 2%) has been evaluated in rabbits. 15 male albino rabbits were treated by the instillation of timolol and aceclidine alone or combined in the conjunctival sac of the right eye. Timolol concentrations in humor aqueous were assayed at 10 min, 30 min, 1 hr, 2 hr, 4 hr and 6 hr after instillation by high-performance liquid chromatography (HPLC). Aceclidine was assayed by a pharmacodynamic method: pupillary diameter at the following time intervals 0 (basal value), 1 min, 5 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr after treatment. Our results demonstrated that no differences in timolol and aceclidine bioavailability were found between simple-drug preparations and their combination.